Gianni Panagiotou

Prof. Dr. Gianni Panagiotou

Microbiome Dynamics · Leitung +49 3641 532-1759 gianni.panagiotou@leibniz-hki.de

Curriculum vitae

Forschungsschwerpunkte
  • Medizinische & Umweltmetagenomik: Mensch, Maus, Pflanzen, marine Lebewesen
  • Systembiologie: Integration von –omics-Daten; Molekül/ Protein & Protein/ Protein Netzwerke
  • Synthetische Biologie: Metabolische Modellierung auf Genomausmaß, Design von Probiotika, Entdeckung von Postbiotika

Publikationen

Seelbinder B#, Lohinai Z*, Vazquez-Uribe R, Brunke S, Chen X, Mirhakkak M, Lopez-Escalera S, Dome B, Megyesfalvi Z, Berta J, Galffy G, Dulka E, Wellejus A, Weiss GJ, Bauer M, Hube B, Sommer MOA, Panagiotou G (2023) Candida expansion in the gut of lung cancer patients associates with an ecological signature that supports growth under dysbiotic conditions. Nat Commun 14(1), 2673.
Soll D, Arunkumar M, Alkhalaf M, Sun S, Nguyen T, Chu C, Lutz V, Schäuble S, Garcia-Ribelles I, Mueller M, Michalke B, Panagiotou G, Schatzlmaier P, Stockinger H, Schamel W, Huber M, Zielinski C (2023) Sodium chloride in the tumor microenvironment enhances T-cell metabolic fitness and cytotoxicity. BioRxiv [Preprint]
Allert S, Schulz D, Kämmer P, Großmann P, Wolf T, Schäuble S, Panagiotou G, Brunke S, Hube B (2022) From environmental adaptation to host survival: Attributes that mediate pathogenicity of Candida auris. Virulence 13(1), 191-214.
Alonso-Roman R, Last A, Mirhakkak MH, Sprague JL, Möller L, Großmann P, Graf K, Gratz R, Mogavero S, Vylkova S, Panagiotou G, Schäuble S, Hube B, Gresnigt MS (2022) Lactobacillus rhamnosus colonisation antagonizes Candida albicans by forcing metabolic adaptations that compromise pathogenicity. Nat Commun 13(1), 3192.
Brandt P, Gerwien F, Wagner L, Krüger T, Ramírez-Zavala B, Mirhakkak MH, Schäuble S, Kniemeyer O, Panagiotou G, Brakhage AA, Morschhäuser J, Vylkova S (2022) Candida albicans SR-like protein kinases regulate different cellular processes: Sky1 is involved in control of ion homeostasis, while Sky2 is important for dipeptide utilization. Front Cell Infect Microbiol 12, 850531.
Jia W, Panagiotou G (2022) Recent advances in diabetes and microbiota. Sci Bull 67(17), 1720-1723. (Review)
Jurburg SD, Eisenhauer N, Buscot F, Chatzinotas A, Chaudhari NM, Heintz-Buschart A, Kallies R, Küsel K, Litchman E, Macdonald CA, Müller S, Reuben RC, Nunes da Rocha U, Panagiotou G, Rillig MC, Singh BK (2022) Potential of microbiome-based solutions for agrifood systems. Nature Food 3(8), 557-560. (Review)
Leung H, Long X, Ni Y, Qian L, Nychas E, Siliceo SL, Pohl D, Hanhineva K, Liu Y, Xu A, Nielsen HB, Belda E, Clément K, Loomba R, Li H, Jia W, Panagiotou G (2022) Risk assessment with gut microbiome and metabolite markers in NAFLD development. Sci Transl Med 14(648), eabk0855.
Russell TJ, De Silva EK, Crowley VM, Shaw-Saliba K, Dube N, Josling G, Pasaje CFA, Kouskoumvekaki I, Panagiotou G, Niles JC, Jacobs-Lorena M, Denise Okafor C, Gamo FJ, Llinás M# (2022) Inhibitors of ApiAP2 protein DNA binding exhibit multistage activity against Plasmodium parasites. PLOS Pathog 18(10), e1010887.
Tappe B, Lauruschkat C, Strobel L, Kurzai O, Rebhan S, Kraus S, Lauruschkat C, Garcia JP, Bussemer L, Possler L, Held M, Huenniger K, Kniemeyer O, Schäuble S, Brakhage AA, Panagiotou G, White L, Einsele H, Löffler J, Wurster S (2022) COVID-19 patients share common, corticosteroid-independent features of impaired host immunity to pathogenic molds. Front Immunol 13, 954985.

Aktuelles